Venture&Growth
Venture&Growth
All Portfolio items
See full Venture&Growth portfolio
IDEA focused on non-invasive topical delivery of approved pain relief drugs.
Following Gilde’s investment in IDEA, the company successfully completed the development of its lead product Diractin®, which treats mild to moderate pain due to osteoarthritis of superficial joints like the knee. After Diractin® was approved in Switzerland, the company sold the early-stage product pipeline to Celtic Pharma. Rights to Diractin were sold to Alpharma Pharmaceuticals, now Pfizer.
IDEA was located in Munich, Germany.
More IDEA news
IDEA AG reports data of a 12-month comparative study of the targeted analgesic Diractin®
IDEA AG gives an update on the development of Diractin®, the targeted analgesic
IDEA AG receives two milestone payments ($37 million) from partner Alpharma
Vesper Medical
US-based MedTech company developing a novel venous stent.
![](https://gildehealthcare.com/wp-content/uploads/2021/05/Vesper-medical.png)
Nyxoah
Belgian Healthtech company focused on the treatment of sleep apnea.
![](https://gildehealthcare.com/wp-content/uploads/2021/05/NYXNOAH.png)
Karius, Inc.
Karius is a U.S.-based diagnostic company that develops and commercializes an AI-based liquid biopsy test...
![](https://gildehealthcare.com/wp-content/uploads/2024/04/Karius-logo-1-Dark.png)